Drawing for ZEMENTRA

USPTO serial 77635704

ZEMENTRA

Reviewed by CopyMark Law Group

Status 605
Filing date
Status date
Registration date
Examiner
KIM, SOPHIA SUJIN
Law office
OFFICE OF TRADEMARK PROGRAM CONTROL

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ZEMENTRA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, gynecological, hematologic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncological, ophthalmological, psychiatric, respiratory, sleep, urogenital and urological, viral diseases and disorders; pharmaceutical preparations for the treatment of allergies, erectile dysfunction, obesity, pain, sexual dysfunction; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations, smoking cessation preparations; pharmaceutical preparations for the treatment of diabetesABANDONED

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 24, 2009MAB5ABANDONMENT NOTICE MAILED - AFTER PUBLICATION
Mar 24, 2009ABN5ABANDONMENT - AFTER PUBLICATION
Mar 19, 2009EXARTEAS EXPRESS ABANDONMENT RECEIVED
Mar 10, 2009PREVLAW OFFICE PUBLICATION REVIEW COMPLETED
Mar 10, 2009ALIEASSIGNED TO LIE
Mar 9, 2009CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Mar 7, 2009DOCKASSIGNED TO EXAMINER
Dec 22, 2008NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance